细胞色素P4502C19基因多态性对介入术后服用氯吡格雷冠心病患者临床预后的影响

目的 探讨细胞色素P450(CYP)2C19 681G>A基因多态性对经皮冠状动脉介入治疗(PCI)后服用氯吡格雷冠心病患者临床预后的影响.方法 入选2009年1月1日至8月31日拟行PCI,并在术后服用氯吡格雷12个月的冠心病患者267例.采用MassARRAY时间飞行质谱检测入选患者CYP2C19 681G>A位点.按基因型不同,将患者分为CYP2C19*1/*1组 (n=130)和CYP2C19*2携带组(n=137).观察两组患者术后1年心绞痛复发、紧急血运重建术、急性心肌梗死、支架内血栓形成和死亡的发生情况.结果 两组患者的临床基本资料差异无统计学意义(P>0.05).PCI术后1年,CYP2C19*2携带组紧急血运重建术和联合终点事件的发生率均高于CYP2C19*1/*1组 (分别为7.3%比1.5%和8.0%比2.3%,P均<0.05).两组患者心绞痛复发、急性心肌梗死、支架内血栓形成和死亡的发生率差异均无统计学意义(P均>0.05).CYP2C19*2携带组随访1年的累积联合终点事件发生风险是CYP2C19*1/*1组的3.59倍(HR=3.59,95%CI:1.02～12.87,P<0.05).结论 CYP2C19 681G>A基因多态性可能是影响PCI术后服用氯吡格雷冠心病患者临床预后的因素.

Abstract：

Objective To investigate the impact of cytochrome P450 (CYP) 2C19 681G>A polymorphism on long-term prognosis of clopidogrel-treated Chinese patients after percutaneous coronary intervention (PCI).Methods Between January 1, 2009 and August 31,2009, 267 patients with coronary heart disease who received PCI and treated with clopidogrel for 12 months were enrolled. CYP2C19*2 was detected by MALDI-TOF MS and patients were grouped into CYP2C19*1/*1(n=130) and CYP2C19*2 carriers group (n=137). Follow-up was 12 months. The primary endpoint was angina recurrence, urgent coronary revascularization, acute myocardial infarction, stent thrombosis, death and the combined end points. Results Baseline data were similar between two groups (P>0.05).Urgent coronary revascularization and the combined end points occurred more frequently in CYP2C19*2 carriers than in CYP2C19*1/*1 patients (7.3% vs. 1.5% and 8.0% vs. 2.3% respectively,all P<0.05). But incidence of angina recurrence, acute myocardial infarction, stent thrombosis and death was similar between two groups (all P>0.05).Hazard risk of 1 year cumulative survival of CYP2C19*2 carriers group was significantly higher than CYP2C19*1/*1 group after PCI (HR=3.59, 95%CI: 1.02-12.87, P<0.05). Conclusion CYP2C19 681G>A polymorphism is a determinant of prognosis in coronary heart disease patients receiving chronic clopidogrel treatment after PCI.

Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention

Objective To investigate the impact of cytochrome P450 (CYP) 2C19 681G>A polymorphism on long-term prognosis of clopidogrel-treated Chinese patients after percutaneous coronary intervention (PCI).Methods Between January 1, 2009 and August 31,2009, 267 patients with coronary heart disease who received PCI and treated with clopidogrel for 12 months were enrolled. CYP2C19*2 was detected by MALDI-TOF MS and patients were grouped into CYP2C19*1/*1(n=130) and CYP2C19*2 carriers group (n=137). Follow-up was 12 months. The primary endpoint was angina recurrence, urgent coronary revascularization, acute myocardial infarction, stent thrombosis, death and the combined end points. Results Baseline data were similar between two groups (P>0.05).Urgent coronary revascularization and the combined end points occurred more frequently in CYP2C19*2 carriers than in CYP2C19*1/*1 patients (7.3% vs. 1.5% and 8.0% vs. 2.3% respectively,all P<0.05). But incidence of angina recurrence, acute myocardial infarction, stent thrombosis and death was similar between two groups (all P>0.05).Hazard risk of 1 year cumulative survival of CYP2C19*2 carriers group was significantly higher than CYP2C19*1/*1 group after PCI (HR=3.59, 95%CI: 1.02-12.87, P<0.05). Conclusion CYP2C19 681G>A polymorphism is a determinant of prognosis in coronary heart disease patients receiving chronic clopidogrel treatment after PCI.